在日本国内，富山化学从2008年1月开始对季节性流感患者实施了“T-705”临床第Ⅱ期实验，初步确认了这种新结构的RNA聚合酶抑制剂对于人体也有药效。同时，通过在日本国内研究所实施的动物实验，“T-705”也被确认对于在全球各国流行的甲型H1N1流感具有治疗效果。
PNAS December 22, 2009, doi: 10.1073/pnas.0909603107
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
Maki Kisoa, Kazumi Takahashib, Yuko Sakai-Tagawaa, Kyoko Shinyac, Saori Sakabea, Quynh Mai Led, Makoto Ozawae,f, Yousuke Furutab and Yoshihiro Kawaokaa,c,e,f,g,1
aDivision of Virology, Department of Microbiology and Immunology
eInternational Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639 Japan
bResearch Laboratories, Toyama Chemical Co., Ltd., Toyama, 930-8508 Japan
d National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
cDepartment of Microbiology and Infectious Diseases, Kobe University, Hyogo, 650-0017 Japan
gExploratory Research for Advanced Technology Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama, 332-0012 Japan
fInfluenza Research Institute, Department of Pathological Sciences, University of Wisconsin-Madison, WI 53706
The neuraminidase inhibitors oseltamivir and zanamivi are used to treat H5N1 influenza. However, oseltamivir-resistant H5N1 viruses have been isolated from oseltamivir-treated patients. Moreover, reassortment between H5N1 viruses and oseltamvir-resistant human H1N1 viruses currently circulating could create oseltamivir-resistant H5N1 viruses, rendering the oseltamivir stockpile obsolete. Therefore, there is a need for unique and effective antivirals to combat H5N1 influenza viruses. The investigational drug T-705 (favipiravir; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has antiviral activity against seasonal influenza viruses and a mouse-adapted H5N1 influenza virus derived from a benign duck virus. However, its efficacy against highly pathogenic H5N1 viruses, which are substantially more virulent, remains unclear. Here, we demonstrate that T-705 effectively protects mice from lethal infection with oseltamivir-sensitive or -resistant highly pathogenic H5N1 viruses. Furthermore, our biochemical analysis suggests that T-705 ribofuranosyl triphosphate, an active form of T-705, acts like purines or purine nucleosides in human cells and does not inhibit human DNA synthesis. We conclude that T-705 shows promise as a therapeutic agent for the treatment of highly pathogenic H5N1 influenza patients. 作者: rojjer 时间: 2015-10-10 11:37
20041063lwt ：
RNA酶抑制剂会对机体产生影响吗？
zaq123321：
Really? It's a good news for humankind. 作者: ghx0123 时间: 2015-10-11 12:33
希望人类可以攻克流感的困扰